| Literature DB >> 33211300 |
N Faccioli1, E Santi2, G Foti3, G Mansueto2, M Corain4.
Abstract
PURPOSE: The purpose of this study was to evaluate the cost-effectiveness of introducing cone-beam computed tomography (CBCT) in the management of the complex finger fractures with articular involvement.Entities:
Keywords: Complex phalangeal fractures; Cone-beam computed tomography; Cost-effectiveness; Finger; Multi-slice computed tomography
Mesh:
Year: 2020 PMID: 33211300 PMCID: PMC9130154 DOI: 10.1007/s12306-020-00687-3
Source DB: PubMed Journal: Musculoskelet Surg ISSN: 2035-5114
Fig. 1Decisional tree for management strategies in finger fracture
Parameters used in Markov model
| Parameters | Baseline estimate | Reference no. |
|---|---|---|
| Prevalence of finger fracture | 10–25% | 1, 2, 4 |
| Pretest probability of a fracture | 1.5–2% | 1–6 |
| Correct diagnosis | 0.98 | 18,19 |
| Probability that the fracture is displaced | 0.12 | 10–13, 42,43 |
| Increased prevalence of non-union for intra-articular fracture | 0.15 | 10–13, 42,43 |
| Increased prevalence of arthritis for intra-articular fracture | 0.784 | 10–13, 42,43 |
| Sensitivity of conventional radiography | 0.70 | 15, 17, 20 |
| Sensitivity of MSCT | 0.90 | 16, 18–22 |
| Specificity of MSCT | 0.98 | 16, 18–22 |
| Sensitivity of CBCT | 0.96 | 17–19, 22, 26–28 |
| Specificity of CBCT | 0.90 | 17–19, 22, 26–28 |
| Cost of plain film X-ray | 32 € | 38 |
| MSCT | 106.23 € | 38 |
| CBCT | 67.33 € | 38 |
| Base case | 0.85 | |
| General population QoL for 30-year-olds | 0.93 | 1,2,4,30 |
| Duration of reduced QoL for complication | ||
| From complex fractures | Lifetime | 10, 32–37 |
| Mean age at time of injury | 35 years | 10, 32–37 |
| Mean age at death | 80 years | 10, 32–37 |
| Immobilization | 0.759 | 32–34 |
| Symptoms (instant decrease) | −0.03 | 32–34 |
CBCT: cone-beam computed tomography. MSCT: multi-slice computed tomography. QoL: quality of life
Results of probabilistic sensitivity analysis for each management strategy
| Conventional radiography | CBCT | MSCT | |
|---|---|---|---|
| Cost per patient (€) | 32 | 67.33 | 106.23 |
| QALYs per patient | 7.9 | 9.08 | 8.18 |
| ICER | Reference | 29.94 | 371.15 |
| NMB at 30,000€ per QALY threshold | 7.89 | 9.07 | 8.09 |
| Incremental NMB | / | 1.17 | 0.19 |
| Ranking | 3rd | 1st | 2nd |
QALY: quality-adjusted life years, ICER: incremental cost-effectiveness ratio, NMB: net monetary benefit
Fig. 2One-way analysis plot for the decision “Diagnosis”. The black horizontal line denotes the expected utility in the reference case. The red line denotes the effectiveness of MSCT, the blue line the effectiveness of CBCT, and the green line the effectiveness without CT. Effectiveness results 8.18 for MSCT and 9.08 for CBCT; the latter is the best choice